Phase 3
N=347
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Coronary Artery Disease (CAD)
Bottom Line
View on ClinicalTrials.gov: NCT00826280 ↗Enrolled (actual)
347
Serious AEs
1.5%
Results posted
Oct 2011
Primary outcome: Primary: Change in Number of Reversible Defects — 0.67; 1.01; 1.00; 0.80 Reversible Defects — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- regadenoson (Drug); overencapsulated caffeine (Drug); technetium (Radiation); placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Astellas Pharma Inc
- Primary completion
- Jul 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Number of Reversible Defects |
0.67; 1.01; 1.00; 0.80; 0.40; 0.38 | <0.001 sig |
| SECONDARY Change in Summed Difference Score (SDS) Across All 17 Segments |
2.24; 2.45; 2.53; 2.36; 1.42; 1.27 | 0.0011 sig |
| SECONDARY Change in Number of Reversible Defects Assessed by Computerized Quantitation |
1.47; 2.00; 2.19; 1.74; 1.46; 1.42 | 0.0037 sig |
| SECONDARY Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation |
3.34; 4.46; 4.29; 4.41; 3.10; 2.46 | <0.001 sig |
| SECONDARY Change From Baseline in Heart Rate |
66.0; 62.0; 64.0; -2.0; -1.0; -2.0 | — |
| SECONDARY Change From Baseline in Systolic Blood Pressure |
135.0; 131.0; 135.0; 0.0; 12.0; 11.0 | — |
| SECONDARY Change From Baseline in Diastolic Blood Pressure |
78.0; 74.0; 73.0; 0.0; 4.0; 6.0 | — |
Summary
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
Eligibility Criteria
Inclusion Criteria
- Subject must have undergone a previous diagnostic study [e.g., SPECT, echocardiography, magnetic resonance imaging (MRI), etc.] for a clinical indication demonstrating evidence of reversible defects in ≥ 1 vascular segment, have had other stress testing within the past 3 months, or the subject's history suggests at least a 50% likelihood of CAD
- If the previous diagnostic study shows only 1 reversible defect and it is in segment 17, another reversible defect will need to be present
- Subject with CAD must have an intermediate/low-risk for immediate intervention
- Subject must ingest caffeinated food or beverages regularly (at least the equivalent of one cup of caffeinated coffee daily)
- Subject must agree to not ingest any caffeine or other foods containing methylxanthine at least 24 hours prior to each study visit
- Subject must agree to abstain from eating solid food or drinking liquids other than water for at least 30 minutes prior to each study visit and 30 minutes following each study visit
Exclusion Criteria
- Subject with documented myocardial infarction (MI) ≤ 30 days prior to enrollment
- Subject with history of percutaneous coronary intervention (PCI) ≤ 4 weeks prior to enrollment
- Subject with history of coronary artery bypass graft (CABG) ≤ 8 weeks prior to enrollment
- Subject has prior history of heart transplantation
- Subject has unstable angina, known severe left main coronary artery stenosis, severe heart failure, uncontrolled arrhythmias, symptomatic hypotension or severe hypertension (systolic blood pressure 180 mmHg, respectively), or > 1st degree atrioventricular block in the absence of a functioning pacemaker
- Subject requires emergent cardiac medical intervention or catheterization
- Subject has a history of smoking, regardless of frequency, tobacco type or method of intake, or using any smoking cessation products, including but not limited to the nicotine patch or nicotine gum, within 3 months prior to first dose of regadenoson
- Subject is currently undergoing treatment with theophylline, or theophylline containing medications within 7 days prior to randomization (Day 3)
- Subject has a history of known or suspected bronchoconstrictive or bronchospastic lung disease [e.g., asthma, wheezing, chronic obstructive pulmonary disease (COPD), etc.]
- Subject has a history of diabetes associated with gastric disorders and/or emptying
- Subject has end stage renal disease (ESRD) with a GFR< 15mL/min or currently undergoing dialysis for ESRD
Data sourced from ClinicalTrials.gov (NCT00826280). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.